Alopecia areata

Concert Pharmaceuticals Completes Enrollment in Open Label Trial to Evaluate Once-Daily vs. Twice-Daily Dosing of CTP-543 in Patients with Alopecia Areata

Retrieved on: 
Mittwoch, Juni 5, 2019
Health, Biotechnology, Clinical trials, Pharmaceutical, Organ systems, Hair diseases, Human hair, RTT, Health, Clinical pharmacology, Hair loss, Alopecia areata, Clinical trial

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has completed patient enrollment of an open label clinical trial to evaluate once-daily compared to twice-daily oral dosing of CTP-543 in patients with alopecia areata.

Key Points: 
  • Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has completed patient enrollment of an open label clinical trial to evaluate once-daily compared to twice-daily oral dosing of CTP-543 in patients with alopecia areata.
  • The open label trial (NCT03811912) is a randomized, multi-center study to evaluate the efficacy and tolerability of once-daily versus twice-daily dosing ofCTP-543, in 57 adult patients with chronic, moderate-to-severe alopecia areata.
  • A second open label trial (NCT03941548) to evaluate once-daily compared to twice-daily oral dosing was initiated in May 2019 and is currently enrolling patients.
  • Concert Pharmaceuticals Inc., theCoNCERT Pharmaceuticals Inc.logo and DCE Platform are registered trademarks ofConcert Pharmaceuticals, Inc. All other trademarks are those of their respective owners.

Concert Pharmaceuticals Announces Initiation of New Open Label Trial to Evaluate Once-Daily vs. Twice-Daily Dosing of CTP-543 in Patients with Alopecia Areata

Retrieved on: 
Donnerstag, Mai 16, 2019
Health, Biotechnology, Clinical trials, Pharmaceutical, Organ systems, Hair diseases, Human hair, RTT, Health, Autoimmune diseases, Incyte, Alopecia areata, Hair loss, Clinical trial

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has initiated a second open label clinical trial to evaluate once-daily compared to twice-daily oral dosing of CTP-543 in patients with alopecia areata.

Key Points: 
  • Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has initiated a second open label clinical trial to evaluate once-daily compared to twice-daily oral dosing of CTP-543 in patients with alopecia areata.
  • We are pleased that our CTP-543 clinical efforts are helping to lead the way to develop a new treatment for alopecia areata.
  • The open label trial will enroll approximately 60 patients with moderate-to-severe alopecia areata in the United States and Canada.
  • Concert Pharmaceuticals Inc., theCoNCERT Pharmaceuticals Inc.logo and DCE Platform are registered trademarks ofConcert Pharmaceuticals, Inc. Jakafi is a registered trademark of Incyte Corporation.

The global alopecia market size is anticipated to reach USD 12.37 billion by 2025

Retrieved on: 
Montag, April 29, 2019
Organ systems, Hair diseases, Human hair, RTT, Alopecia areata, Hair loss, Pattern hair loss

NEW YORK, April 29, 2019 /PRNewswire/ -- Alopecia Market Size, Share & Trends Analysis Report By Disease Type (Alopecia Areata, Androgenetic Alopecia), By End Use, By Sales Channel, By Gender, By Region, And Segment Forecasts, 2019 - 2025

Key Points: 
  • NEW YORK, April 29, 2019 /PRNewswire/ -- Alopecia Market Size, Share & Trends Analysis Report By Disease Type (Alopecia Areata, Androgenetic Alopecia), By End Use, By Sales Channel, By Gender, By Region, And Segment Forecasts, 2019 - 2025
    The global alopecia market size is anticipated to reach USD 12.37 billion by 2025.
  • Based on condition, the market is classified into alopecia areata, androgenetic alopecia, and others.
  • Androgenetic alopecia segment led the market in 2018 with revenue of USD 7,242.7 million and is anticipated to grow at a lucrative CAGR over the forecast period.
  • On the other hand, alopecia areata is anticipated to expand at the fastest CAGR of 6.3% over the forecast period.

Global $12+ Billion Alopecia Market Forecast, 2025 - ResearchAndMarkets.com

Retrieved on: 
Montag, April 29, 2019
Professional services, Consulting, Organ systems, Hair diseases, Human hair, RTT, Autoimmune diseases, Alopecia areata, Pattern hair loss, Hair loss

The " Alopecia Market Size, Share & Trends Analysis Report By Disease Type (Alopecia Areata, Androgenetic Alopecia), By End Use, By Sales Channel, By Gender, By Region, And Segment Forecasts, 2019 - 2025 " report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The " Alopecia Market Size, Share & Trends Analysis Report By Disease Type (Alopecia Areata, Androgenetic Alopecia), By End Use, By Sales Channel, By Gender, By Region, And Segment Forecasts, 2019 - 2025 " report has been added to ResearchAndMarkets.com's offering.
  • The global alopecia market size is anticipated to reach USD 12.37 billion by 2025.
  • Based on condition, the market is classified into alopecia areata, androgenetic alopecia, and others.
  • On the basis of end use, the alopecia market is segmented into homecare settings and dermatology clinics.

Concert Pharmaceuticals to Present CTP-543 Phase 2 Interim Data in Alopecia Areata at 2019 World Congress for Hair Research Annual Meeting

Retrieved on: 
Donnerstag, April 11, 2019
Health, Biotechnology, Pharmaceutical, Other Health, General Health, Organ systems, Hair diseases, Human hair, RTT, Autoimmune diseases, Alopecia areata, Hair loss

Deuterium modification of ruxolitinib was found to alter its human pharmacokinetics in ways which may enhance its use as a treatment for alopecia areata.

Key Points: 
  • Deuterium modification of ruxolitinib was found to alter its human pharmacokinetics in ways which may enhance its use as a treatment for alopecia areata.
  • The scalp is the most commonly affected area, but any hair-bearing site can be affected alone or together with the scalp.
  • Onset of the disease can occur throughout life with the majority of patients initially having symptoms by age 40.
  • Concert Pharmaceuticals Inc., theCoNCERT Pharmaceuticals Inc.logo and DCE Platform are registered trademarks ofConcert Pharmaceuticals, Inc. Jakafi is a registered trademark of Incyte Corporation.

Concert Pharmaceuticals Announces Initiation of Open Label Trial to Evaluate Once-Daily vs. Twice-Daily Dosing of CTP-543 in Patients with Alopecia Areata

Retrieved on: 
Mittwoch, März 6, 2019
Health, Biotechnology, Clinical trials, Pharmaceutical, Organ systems, Hair diseases, Human hair, RTT, Animal anatomy, Incyte, Hair loss, Alopecia areata

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has initiated an open label clinical trial to evaluate once-daily compared to twice-daily oral dosing of CTP-543 in patients with alopecia areata.

Key Points: 
  • Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has initiated an open label clinical trial to evaluate once-daily compared to twice-daily oral dosing of CTP-543 in patients with alopecia areata.
  • This open label trial will allow us to further understand CTP-543s effect when dosed once daily, said James Cassella, Ph.D., Chief Development Officer of Concert Pharmaceuticals.
  • Approximately 60 patients with moderate-to-severe alopecia areata are expected to be enrolled in the open label trial, which will be conducted in the United States.
  • Concert Pharmaceuticals Inc., theCoNCERT Pharmaceuticals Inc.logo and DCE Platform are registered trademarks ofConcert Pharmaceuticals, Inc. Jakafi is a registered trademark of Incyte Corporation.

Concert Pharmaceuticals Presents Interim CTP-543 Phase 2 Data in Alopecia Areata during Late-Breaker Session at American Academy of Dermatology Annual Meeting

Retrieved on: 
Freitag, März 1, 2019
Health, Biotechnology, Clinical trials, Pharmaceutical, General Health, Hair diseases, Human hair, RTT, Anatomy, Autoimmune diseases, Hair loss, Alopecia totalis, Alopecia areata, Medicine, Zoology

Patients with moderate-to-severe alopecia areata enrolled in the first two cohorts received 4 mg or 8 mg of CTP-543 twice-daily or placebo twice-daily for 24 weeks.

Key Points: 
  • Patients with moderate-to-severe alopecia areata enrolled in the first two cohorts received 4 mg or 8 mg of CTP-543 twice-daily or placebo twice-daily for 24 weeks.
  • The responders in the 8 mg twice-daily dose group were evenly distributed among patients with patchy alopecia areata and the more severe forms, alopecia totalis and alopecia universalis.
  • The most common side effects in the interim analysis were headache, upper respiratory tract infection, cough, acne and nausea.
  • Concert Pharmaceuticals Inc., theCoNCERT Pharmaceuticals Inc.logo and DCE Platform are registered trademarks ofConcert Pharmaceuticals, Inc. Jakafi is a registered trademark of Incyte Corporation.

TARGET PharmaSolutions® Launches TARGET-DERM Real-World Observational Study to Advance the Understanding of Atopic Dermatitis (Eczema) and Other Immune-Mediated Inflammatory Skin Conditions

Retrieved on: 
Mittwoch, Februar 13, 2019
RTT, Organ systems, Medical specialties, Immunology, Autoimmune diseases, Type I hypersensitivity, Dermatitis, Vitiligo, Atopic dermatitis, Atopy, Hidradenitis, Alopecia areata

The study will deliver real-world evidence for several immune-mediated inflammatory skin conditions (IMISCs), initially focusing on patients with atopic dermatitis (AD/eczema).

Key Points: 
  • The study will deliver real-world evidence for several immune-mediated inflammatory skin conditions (IMISCs), initially focusing on patients with atopic dermatitis (AD/eczema).
  • TARGET-DERM will eventually include the skin conditions hidradenitis suppurativa (painful bumps under the skin), alopecia areata (autoimmune-related hair loss), and vitiligo (loss of skin pigment).
  • "We are excited to initiate enrollment and to advance the important work of further understanding inflammatory skin diseases and particularly AD, through this TARGET-DERM registry," said Dr. Guttman-Yassky.
  • "There are many critical, unanswered questions regarding the mechanisms underlying eczema and these other complex immune-mediated skin conditions.

Concert Pharmaceuticals Selected for Late-Breaking Oral Presentation of CTP-543 Phase 2 Data in Alopecia Areata at 2019 AAD Annual Meeting

Retrieved on: 
Montag, Februar 11, 2019
Health, Biotechnology, Clinical trials, Pharmaceutical, Organ systems, Hair diseases, Human hair, RTT, Animal anatomy, Autoimmune diseases, Alopecia areata, Hair loss

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that interim clinical data from its CTP-543 Phase 2 trial in alopecia areata has been selected for an oral presentation at the Late-Breaking Research Program during the American Academy of Dermatology (AAD) Annual Meeting being held March 1 - 5, 2019 in Washington, D.C.

Key Points: 
  • Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that interim clinical data from its CTP-543 Phase 2 trial in alopecia areata has been selected for an oral presentation at the Late-Breaking Research Program during the American Academy of Dermatology (AAD) Annual Meeting being held March 1 - 5, 2019 in Washington, D.C.
  • Deuterium modification of ruxolitinib was found to alter its human pharmacokinetics in ways which may enhance its use as a treatment for alopecia areata.
  • The scalp is the most commonly affected area, but any hair-bearing site can be affected alone or together with the scalp.
  • Concert Pharmaceuticals Inc., theCoNCERT Pharmaceuticals Inc.logo and DCE Platform are registered trademarks ofConcert Pharmaceuticals, Inc. Jakafi is a registered trademark of Incyte Corporation.

Concert Pharmaceuticals Completes Enrollment of 12 mg Cohort in Phase 2a Trial of CTP-543 in Alopecia Areata

Retrieved on: 
Dienstag, Januar 22, 2019
Health, Biotechnology, Clinical trials, Pharmaceutical, FDA, Organ systems, Hair diseases, Human hair, RTT, Animal anatomy, Alopecia areata, Hair loss, Pyrimidines

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has completed patient enrollment of the final cohort evaluating 12 mg twice daily of CTP-543 in its Phase 2a trial for the treatment of moderate-to-severe alopecia areata.

Key Points: 
  • Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has completed patient enrollment of the final cohort evaluating 12 mg twice daily of CTP-543 in its Phase 2a trial for the treatment of moderate-to-severe alopecia areata.
  • Data from the Phase 2a trial including the 12 mg cohort is expected in the third quarter of 2019.
  • The Phase 2a trial is a double-blind, randomized, placebo-controlled, sequential dose trial to evaluate the safety and efficacy of CTP-543 in adult patients with moderate-to-severe alopecia areata.
  • In November 2018, Concert reported positive interim topline results from the first two cohorts (4 mg and 8 mg twice daily) in its Phase 2a trial.